AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28268134 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited physical activity
Number of subjects: 324
Study 28268134 — intervention group
Group type: EXPERIMENTAL
Intervention: Very poorly controlled asthma symptoms
Number of subjects: 324
Study 28268134 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity limitation
Number of subjects: 324
Study 28268358 — intervention group
Group type: EXPERIMENTAL
Intervention: EDA-Gram representation of electrodermal activity (EDA) signals
Number of subjects: 0
Study 28268358 — intervention group
Group type: EXPERIMENTAL
Intervention: Derived features from EDA-Gram
Number of subjects: 0
Study 28270022 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-42, an oral pan-HDAC inhibitor, 40 mg dosed three times weekly for three weeks of a 28-day cycle
Number of subjects: 0
Study 28270092 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Track® CMV
Number of subjects: 124
Study 28270092 — intervention group
Group type: COMPARATOR
Intervention: QuantiFERON®-CMV
Number of subjects: 124
Study 28270092 — intervention group
Group type: COMPARATOR
Intervention: iTAg™ MHC Tetramer
Number of subjects: 124
Study 28270092 — intervention group
Group type: COMPARATOR
Intervention: iTAg™ MHC Tetramers
Number of subjects: 124
Study 28270121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic prostate adaptive radiotherapy utilizing Kilovoltage Intrafraction Monitoring (KIM)
Number of subjects: 48
Study 28270121 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (not explicitly mentioned in the abstract)
Number of subjects: 48
Study 28270136 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients referred from different hospitals
Number of subjects: 394
Study 28270136 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased travel distance to the regional centre
Number of subjects: 394
Study 28270136 — intervention group
Group type: COMPARATOR
Intervention: Patients from each hospital
Number of subjects: 394
Study 28270136 — intervention group
Group type: COMPARATOR
Intervention: Annual operation rate for PC
Number of subjects: 394
Study 28270136 — intervention group
Group type: COMPARATOR
Intervention: Median travel distance for patients from the five hospitals
Number of subjects: 394
Study 28270162 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of paclitaxel (50 mg/m) and 5-fluorouracil (5-FU) with concurrent radiation therapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx) followed by 2 cycles of consolidation chemotherapy
Number of subjects: 53
Study 28270167 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia/Sedation (A/S) practices
Number of subjects: 6680
Study 28270167 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Assessment (PA) practices
Number of subjects: 6680
Study 28270212 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150 μg every other week combined with hCG twice-weekly for 52 weeks
Number of subjects: 18
Study 28270435 — intervention group
Group type: EXPERIMENTAL
Intervention: Multikinase inhibitors initiated at study entry (cohort 1)
Number of subjects: 700
Study 28270435 — intervention group
Group type: COMPARATOR
Intervention: No multikinase inhibitors initiated at study entry (cohort 2)
Number of subjects: 700
Study 28270536 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater tract-level social disorder
Number of subjects: 737
Study 28270536 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater tract-level social disadvantage
Number of subjects: 737
Study 28270757 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditative Movement practices (12 hours of training)
Number of subjects: 14
Study 28270916 — intervention group
Group type: EXPERIMENTAL
Intervention: Active knowledge translation intervention (audit and feedback, patient- and provider-directed educational tools delivered at a comprehensive in-person medical detailing visit)
Number of subjects: 55
Study 28270916 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 55
Study 28270924 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 80
Study 28270924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28271017 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation by practice facilitators (PFs)
Number of subjects: 84
Study 28271017 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 84
Study 28271017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enablers of implementation
Number of subjects: 84
Study 28271017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implementation success
Number of subjects: 84
Study 28271639 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) using CyberKnife technology, 36.25 Gy in five fractions
Number of subjects: 45
Study 28271639 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) using CyberKnife technology
Number of subjects: 45
Study 28273222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 28273780 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs) - 33% oral, 66% injectable
Number of subjects: 66
Study 28273780 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 66
Study 28273780 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement in adherence
Number of subjects: 66
Study 28273780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DMTs
Number of subjects: 66
Study 28274211 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose ablative radiation treatment (20 Gy to the tumor and 15 Gy to the tumor bed)
Number of subjects: 25
Study 28274221 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Assessment Program through EMS (CHAP-EMS)
Number of subjects: 79
Study 28274235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-epiglottic baton plate (PEBP) treatment
Number of subjects: 49
Study 28274254 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different dosing regimens for the maintenance of remission in ulcerative colitis (CODA study)
Number of subjects: 0
Study 28274254 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered treatment (ZICE study)
Number of subjects: 0
Study 28274254 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered treatment (ZICE study)
Number of subjects: 0
Study 28274904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HIV prevention package including HIV testing and counseling, voluntary medical circumcision, condoms for males, PrEP, conditional cash transfer, contraceptives for females, and referrals for HIV care.
Number of subjects: 0
Study 28274904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health teams delivering the combination HIV prevention package.
Number of subjects: 0
Study 28274904 — intervention group
Group type: EXPERIMENTAL
Intervention: Age- and gender-specific combination HIV prevention interventions.
Number of subjects: 0
Study 28274957 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28274963 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal MRI (structural MRI, functional MRI, diffusion tensor imaging) in aMCI group
Number of subjects: 240
Study 28274963 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal MRI (structural MRI, functional MRI, diffusion tensor imaging) in VaMCI group
Number of subjects: 240
Study 28274963 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation in aMCI group
Number of subjects: 240
Study 28274963 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation in VaMCI group
Number of subjects: 240
Study 28274963 — intervention group
Group type: COMPARATOR
Intervention: Neuropsychological evaluation in NC group
Number of subjects: 240
Study 28275099 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score
Number of subjects: 0
Study 28275099 — intervention group
Group type: COMPARATOR
Intervention: Other Diet Quality Indexes
Number of subjects: 0
Study 28275101 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal dietary protein intake
Number of subjects: 0
Study 28275119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilaralisib (200 mg QD) in combination with paclitaxel and carboplatin
Number of subjects: 58
Study 28275119 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin
Number of subjects: 58
Study 28275165 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFEHEART risk equation
Number of subjects: 2404
Study 28275165 — intervention group
Group type: COMPARATOR
Intervention: modified Framingham risk equation
Number of subjects: 2404
Study 28275165 — intervention group
Group type: COMPARATOR
Intervention: American College of Cardiology/American Heart Association ASCVD Pooled Cohort Risk Equations
Number of subjects: 2404
Study 28275165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal incident ASCVD
Number of subjects: 2404
Study 28275165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal incident ASCVD
Number of subjects: 2404
Study 28275176 — intervention group
Group type: EXPERIMENTAL
Intervention: saHBEC co-cultured with moDC
Number of subjects: 2
Study 28275176 — intervention group
Group type: COMPARATOR
Intervention: cHBEC co-cultured with moDC
Number of subjects: 2
Study 28275176 — intervention group
Group type: EXPERIMENTAL
Intervention: saHBEC stimulated with particulate matter
Number of subjects: 2
Study 28275176 — intervention group
Group type: COMPARATOR
Intervention: cHBEC stimulated with particulate matter
Number of subjects: 2
Study 28275197 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD signal temporal delay
Number of subjects: 30
Study 28275197 — intervention group
Group type: EXPERIMENTAL
Intervention: DSC-MRI parameters (Tmax, mean transit time, cerebral blood flow, cerebral blood volume)
Number of subjects: 30
Study 28275197 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver-operator characteristic (ROC) analysis for severe hypoperfusion (Tmax >6 seconds)
Number of subjects: 30
Study 28275886 — intervention group
Group type: EXPERIMENTAL
Intervention: mRECIST (modified RECIST 1.1)
Number of subjects: 36
Study 28275886 — intervention group
Group type: EXPERIMENTAL
Intervention: RANO-HGG (RANO high-grade glioma)
Number of subjects: 36
Study 28275886 — intervention group
Group type: COMPARATOR
Intervention: RECIST 1.1
Number of subjects: 36
Study 28275886 — intervention group
Group type: COMPARATOR
Intervention: RANO-BM (RANO brain metastasis)
Number of subjects: 36
Study 28275958 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 8
Study 28275958 — intervention group
Group type: COMPARATOR
Intervention: Other DPP-4 inhibitors (linagliptin, saxagliptin, sitagliptin, vildagliptin) at their recommended daily doses
Number of subjects: 8
Study 28275966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) program delivered by breast cancer survivors (compañeras)
Number of subjects: 80
Study 28275966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) program
Number of subjects: 80
Study 28276900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary soluble fibres developed by enzymatic synthesis with α-(1,2) branching
Number of subjects: 0
Study 28276900 — intervention group
Group type: EXPERIMENTAL
Intervention: α-(1,3)-linked and α-(1,6)-linked glucose oligomers
Number of subjects: 0
Study 28277107 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 509
Study 28277349 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy during pregnancy (various adherence levels and durations)
Number of subjects: 1857
Study 28277349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery (elective and nonelective)
Number of subjects: 1857
Study 28277349 — intervention group
Group type: EXPERIMENTAL
Intervention: No antiretroviral therapy during pregnancy
Number of subjects: 1857
Study 28277349 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load greater than 1,000 copies/mL
Number of subjects: 1857
Study 28277363 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative technique
Number of subjects: 28
Study 28277363 — intervention group
Group type: COMPARATOR
Intervention: Standardized technique
Number of subjects: 28
Study 28277702 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session group-based weekly comprehensive trauma management and smoking cessation treatment focusing on skills to alleviate PTSD symptoms.
Number of subjects: 90
Study 28277735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa symptoms
Number of subjects: 0
Study 28278476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical Brain-Computer Interfaces (BCIs)
Number of subjects: 0
Study 28279376 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging use in treatment decision-making for valvular heart disease
Number of subjects: 0
Study 28279376 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial data
Number of subjects: 0
Study 28279376 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge gaps in imaging use
Number of subjects: 0
Study 28279641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at 4 mA
Number of subjects: 18
Study 28279891 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50-200mg/day
Number of subjects: 1160
Study 28279891 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day
Number of subjects: 1160
Study 28279891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 28279891 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 1160
Study 28280103 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel treatment; genetic polymorphisms assessed by MassARRAY method.
Number of subjects: 249
Study 28280134 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genomic evaluation including whole exome sequencing, deletion and CNV analyses
Number of subjects: 61
Study 28280134 — intervention group
Group type: COMPARATOR
Intervention: Healthy mutation-negative individuals (control group)
Number of subjects: 61
Study 28280887 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 2.0 mg/kg bid (maximum 100 mg bid for body weight >50 kg)
Number of subjects: 96
Study 28280887 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam co-administered with phenobarbital
Number of subjects: 96
Study 28280887 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam co-administered with carbamazepine
Number of subjects: 96
Study 28280887 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam co-administered with valproate
Number of subjects: 96
Study 28280901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (screening plus training and support in intensive multifactorial treatment)
Number of subjects: 21513
Study 28280901 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (screening plus routine care of individuals with screen-detected diabetes)
Number of subjects: 21513
Study 28280971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022859 infused IV at 1.25 mg/kg over 1 h every 2 weeks (cohort 1A)
Number of subjects: 14
Study 28280971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022859 infused IV at flat doses of 12.5 mg (cohort 1B)
Number of subjects: 14
Study 28280971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022859 infused IV at flat doses of 25 mg (cohort 2)
Number of subjects: 14
Study 28280971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022859 at 25 mg dose level after fifth infusion
Number of subjects: 14
Study 28281183 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg/daily) plus high dose carboplatin (AUC 6) and paclitaxel (200 mg/m2) in Cohort A
Number of subjects: 14
Study 28281183 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg/daily) plus standard dose carboplatin (AUC 5) and paclitaxel (175 mg/m2) in Cohort B
Number of subjects: 14
Study 28281183 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate for both cohorts
Number of subjects: 14
Study 28281228 — intervention group
Group type: EXPERIMENTAL
Intervention: RISQ-PATH score (≥10 points)
Number of subjects: 178
Study 28281228 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline QTc-interval
Number of subjects: 178
Study 28281228 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up QTc-interval
Number of subjects: 178
Study 28281228 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall QTc-interval change
Number of subjects: 178
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ASA + clopidogrel)
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 608
Study 28281731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 608
Study 28281907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (HAB; Twinrix™, GSK Vaccines, Belgium)
Number of subjects: 307
Study 28281907 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge dose of monovalent hepatitis A vaccine (N=2) or hepatitis B vaccine (N=2)
Number of subjects: 307
Study 28281907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical modeling based on immunogenicity results
Number of subjects: 307
Study 28282271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambda/RBV/DCV for 12 weeks, followed by Lambda/RBV for an additional 12 weeks in cohort A; response-guided therapy in cohort B.
Number of subjects: 300
Study 28282271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambda/RBV/DCV
Number of subjects: 300
Study 28282585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.7 g/day of EPA+DHA)
Number of subjects: 191
Study 28282585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1.8 g/day of EPA+DHA)
Number of subjects: 191
Study 28282612 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily for 2 years
Number of subjects: 38
Study 28282612 — intervention group
Group type: COMPARATOR
Intervention: Nilotinib
Number of subjects: 38
Study 28282878 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Neighborhood Checklist (the Checklist)
Number of subjects: 82
Study 28283497 — intervention group
Group type: EXPERIMENTAL
Intervention: Limit of detection (LOD, hs-cTnI<2 ng/L)
Number of subjects: 2828
Study 28283497 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cutoff (hs-cTnI<5 ng/L)
Number of subjects: 2828
Study 28283497 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour algorithm (hs-cTnI<5 ng/L and 1-hour change<2 ng/L)
Number of subjects: 2828
Study 28283497 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-hour algorithm (recommended in the European Society of Cardiology guideline)
Number of subjects: 2828
Study 28283511 — intervention group
Group type: EXPERIMENTAL
Intervention: Wirion Embolic Protection System
Number of subjects: 120
Study 28283511 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 120
Study 28283596 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 U
Number of subjects: 155
Study 28283596 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 600 U
Number of subjects: 155
Study 28283596 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 600-800 U
Number of subjects: 155
Study 28283596 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (all doses)
Number of subjects: 155
Study 28283605 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased oxygen extraction fraction (OEF)
Number of subjects: 49
Study 28283605 — intervention group
Group type: COMPARATOR
Intervention: Normal oxygen extraction fraction (OEF)
Number of subjects: 49
Study 28283605 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased OEF (per hemisphere)
Number of subjects: 49
Study 28283605 — intervention group
Group type: EXPERIMENTAL
Intervention: Censored patients due to revascularization surgery
Number of subjects: 49
Study 28283699 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung strategy with PEEP 15 cmH2O
Number of subjects: 33
Study 28283699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose end-expiratory CT scans at PEEP 5 and 15 cmH2O
Number of subjects: 33
Study 28283746 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 (ES3) valve
Number of subjects: 335
Study 28283746 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline first degree atrioventricular block (AVB)
Number of subjects: 335
Study 28283746 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural complete right bundle branch block (RBBB)
Number of subjects: 335
Study 28283746 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block after TAVI
Number of subjects: 335
Study 28283746 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline first degree AVB
Number of subjects: 335
Study 28283746 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural complete RBBB
Number of subjects: 335
Study 28283746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversizing and implantation depth
Number of subjects: 335
Study 28283904 — intervention group
Group type: EXPERIMENTAL
Intervention: ePrognosis score 0-2
Number of subjects: 971
Study 28283904 — intervention group
Group type: EXPERIMENTAL
Intervention: ePrognosis score 3-6
Number of subjects: 971
Study 28283904 — intervention group
Group type: EXPERIMENTAL
Intervention: ePrognosis score 7-10
Number of subjects: 971